Completed PHASE3 INTERVENTIONAL 2-arm NCT05191186

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy (ILITNU)

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy in a Phase III Randomized, Parallel Group Placebo Controlled Double Blind Multisite Field Trial

Sponsor: Aarhus University Hospital

Conditions Allergic Asthma Allergic Conjunctivitis of Both Eyes Allergic Rhinitis Due to Grass Pollen

Interventions Grass pollen extract - Alutard Phleum pratense, ALK

Updated 5 times since 2022 Last updated: Aug 7, 2025 Started: Feb 1, 2020 Primary completion: Aug 1, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Allergic Asthma and Allergic Conjunctivitis of Both Eyes, this trial is completed. The trial is conducted by Aarhus University Hospital and has accumulated 5 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3

Status: Unknown → Completed
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Feb 2024 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Active Not Recruiting → Unknown Status
Feb 2022 — Feb 2024 [monthly]

Active Not Recruiting PHASE3

First recorded

Feb 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aarhus University Hospital
University Hospital, Linkoeping
University of Aarhus

Data source: Aarhus University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aarhus, Denmark
• Linköping, Sweden